PharmAbcine to Present Immuno-Oncology Research Results at AACR in April

[Asia Economy Reporter Hyungsoo Park] Antibody therapeutic developer PharmAbcine announced on the 2nd that it will present research results on the next-generation immuno-oncology drug PMC-309 at the American Association for Cancer Research (AACR) next month.

PharmAbcine will additionally disclose research results related to the anti-tumor efficacy of PMC-309, which were announced last year at AACR. It introduced that it confirmed an increase in immune activity within the tumor microenvironment due to PMC-309. The research abstract will be posted on the AACR 2022 site on the 8th of this month, local US time, and the poster will be posted on the 10th of next month.

PMC-309 is an immuno-oncology drug that binds to VISTA (V-domain Ig-containing suppressor of T-cell activation), which is expressed on immunosuppressive cells, and blocks the function of immunosuppressive cells, thereby increasing the activation of T cells in the tumor microenvironment. VISTA is emerging as a new target for immuno-oncology drugs. T cells are immune cells that have the function of directly killing and removing virus-infected cells.

Unlike existing immune checkpoint inhibitors targeting T cells, PMC-309 specifically binds to VISTA expressed on immunosuppressive cells. It is an antibody drug candidate discovered independently using PharmAbcine's fully human antibody library and is conducting nonclinical tasks under the national new drug development project led by the Korea Drug Development Fund (KDDF).

Dr. Chunho Park of PharmAbcine introduced, "PMC-309, with its differentiated mechanism, will be a new treatment for patients who do not respond to existing PD-1/PD-L1 therapies." He added, "Toxicity tests for submitting Investigational New Drug (IND) applications are in the final stages," and "We will focus on sharing with various experts to complete the protocol for a successful Phase 1 clinical trial."

This content was produced with the assistance of AI translation services.